SK Group completed the acquisition of YpoKesi.

SK Group completed the acquisition of YpoKesi, a producer of gene and cell therapy products. Financial terms were not disclosed. "We are glad to advance into the gene therapy CMO business by investing in Yposkesi which has great capability and potential. We will spare no efforts to help Yposkesi grow fast in the global market," Jang Dong-Hyun, SK Group CEO.